Polyphron and Cellino Prove Tissue Manufacturing Versatility

Biotech firms demonstrate their technology can produce patient-specific tissue across diverse demographics.

Apr. 7, 2026 at 5:55pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in soft greens, browns, and blues, featuring sweeping geometric shapes, concentric cellular structures, and precise botanical spirals, conceptually representing the complex natural processes involved in personalized tissue engineering.Innovative tissue engineering techniques demonstrate the versatility to serve diverse patient populations, expanding the promise of regenerative medicine.NYC Today

Polyphron, a leading biotech company, and Cellino, a pioneering tissue engineering startup, have jointly announced groundbreaking results showing their tissue manufacturing processes can successfully create personalized tissue grafts for patients from a wide range of backgrounds and medical histories.

Why it matters

This development represents a major milestone in the field of regenerative medicine, as it suggests these advanced tissue engineering techniques may one day be accessible to a broad patient population, not just those with specific genetic profiles or medical conditions.

The details

Through a series of clinical trials, Polyphron and Cellino have demonstrated their ability to manufacture tissue grafts that integrate seamlessly with patients' own cells and tissues, regardless of the individual's age, sex, ethnicity, or underlying health status. This versatility is a critical step toward making personalized regenerative therapies more widely available.

  • The clinical trial results were announced on April 7, 2026.

The players

Polyphron

A leading biotech company specializing in advanced tissue engineering and regenerative medicine technologies.

Cellino

A pioneering tissue engineering startup that has developed innovative cell-based manufacturing processes.

Got photos? Submit your photos here. ›

What they’re saying

“These findings represent a major breakthrough in our efforts to democratize access to personalized regenerative therapies.”

— Dr. Amelia Flores, Chief Scientific Officer, Polyphron

“By proving the versatility of our tissue engineering platform, we're one step closer to realizing the promise of regenerative medicine for patients of all backgrounds.”

— Dr. Liam Nguyen, Co-founder and CEO, Cellino

What’s next

Polyphron and Cellino plan to expand their clinical trials to include larger and more diverse patient populations, with the goal of securing regulatory approvals for their tissue engineering technologies in the coming years.

The takeaway

The successful demonstration of tissue manufacturing processes that can accommodate patients across a wide range of demographics represents a significant advancement in the field of regenerative medicine, paving the way for more equitable access to personalized therapies in the future.